Equillium Results Presentation Deck

EQUALISE Study Design: Type A - Systemic Lupus Erythematosus (without Lupus Nephritis) equalise Phase 1b open-label, dose escalation study Type A Patients with active or inactive SLE without known lupus nephritis 2 doses itolizumab SC, Days 1 & 15 N = 35 equillium Cohort 1: 0.4 mg/kg Cohort 2: 0.8 mg/kg Cohort 3: 1.6 mg/kg Cohort 4: 2.4 mg/kg Cohort 5: 3.2 mg/kg Type A Completed Primary Objective • Assess the safety and tolerability of itolizumab in subjects with systemic lupus erythematosus (SLE) with and without active proliferative lupus nephritis Secondary Objective • Characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of itolizumab Abbreviations: PK pharmacokinetics, PD pharmacodynamics, SC subcutaneous, SLE systemic lupus erythematosus, Putterman et al., PO1623 ASN, 2021 15

View entire presentation